Collaborative Trajectory Analysis Project is Drug Discovery in United States that focus on developer business. Founded in 2016. They cover business area such as developer, collaboration, different stakeholder, critical problem, Duchenne drug development, leader, Duchenne muscular dystrophy research, collaborative datum science, clinical trial design, expert, effective new therapy, patient.
2016
( 8 years old in 2024 )
Developer
-
One Broadway
Cambridge Innovative Center
Cambridge, MA 02142
United States
Private
developercollaborationdifferent stakeholdercritical problemDuchenne drug developmentleaderDuchenne muscular dystrophy researchcollaborative datum scienceclinical trial designexperteffective new therapypatient
* We use standard office opening hours in near Collaborative Trajectory Analysis Project's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Collaborative Trajectory Analysis Project is Drug Discovery business from United States that founded in 2016 (8 years old in 2024), Collaborative Trajectory Analysis Project business is focusing on Developer.
Collaborative Trajectory Analysis Project headquarter office and corporate office address is located in One Broadway Cambridge Innovative Center Cambridge, MA 02142 United States.
Collaborative Trajectory Analysis Project was founded in United States.
In 2024, Collaborative Trajectory Analysis Project is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Collaborative Trajectory Analysis Project, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
